疾病
医学
转录组
细胞
糖尿病
肾脏疾病
计算生物学
细胞生物学
生物
生物信息学
内科学
内分泌学
基因
遗传学
基因表达
作者
Hao Wu,Romer A. González-Villalobos,Xiang Yao,Dermot F. Reilly,Tao Chen,Matthew M. Rankin,Eugene Myshkin,Matthew Douglas Breyer,Benjamin D. Humphreys
出处
期刊:Cell Metabolism
[Cell Press]
日期:2022-06-15
卷期号:34 (7): 1064-1078.e6
被引量:258
标识
DOI:10.1016/j.cmet.2022.05.010
摘要
Diabetic kidney disease (DKD) occurs in ∼40% of patients with diabetes and causes kidney failure, cardiovascular disease, and premature death. We analyzed the response of a murine DKD model to five treatment regimens using single-cell RNA sequencing (scRNA-seq). Our atlas of ∼1 million cells revealed a heterogeneous response of all kidney cell types both to DKD and its treatment. Both monotherapy and combination therapies targeted differing cell types and induced distinct and non-overlapping transcriptional changes. The early effects of sodium-glucose cotransporter-2 inhibitors (SGLT2i) on the S1 segment of the proximal tubule suggest that this drug class induces fasting mimicry and hypoxia responses. Diabetes downregulated the spliceosome regulator serine/arginine-rich splicing factor 7 (Srsf7) in proximal tubule that was specifically rescued by SGLT2i. In vitro proximal tubule knockdown of Srsf7 induced a pro-inflammatory phenotype, implicating alternative splicing as a driver of DKD and suggesting SGLT2i regulation of proximal tubule alternative splicing as a potential mechanism of action for this drug class.
科研通智能强力驱动
Strongly Powered by AbleSci AI